ASCO 2023 Highlights Podcast

In this episode (20:25), Medicom’s correspondent covers 6 presentations from the annual meeting of the American Society for Clinical Oncology (ASCO 2023), held in Chicago, IL, USA, from 2-6 June 2023.
The topics discussed are:

1. De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior
   The 5 years results of the PROSPECT trial showed that pre-operative chemotherapy (FOLFOX) with selective pelvic chemoradiation is non-inferior to neoadjuvant pelvic chemoradiation.
2. SONIA: No survival benefit with first-line vs second-line CDK4/6 inhibition in metastatic breast cancer
   CDK4/6 inhibition in first line compared with second line did not improve survival nor quality of life. Instead, it extended time on the CDK4/6 inhibitor, increased the incidence of grade 3-4 toxicity, and increased drug expenditure in the randomised, phase 3 SONIA trial
3. Addition of pembrolizumab to perioperative chemotherapy improves event-free survival in patients with early-stage NSCLC
   Neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab improved event-free survival in patients with early-stage non-small cell lung cancer (NSCLC) compared with neoadjuvant chemotherapy and surgery alone, as shown by the results from KEYNOTE-671.
4. Post-checkpoint inhibitor erdafitinib outperforms chemotherapy in patients with FGFR-altered advanced urothelial cancer
   Patients with FGFR-altered advanced urothelial cancer who progress on or after first- or second-line anti-PD-(L)1 treatment benefitted from the pan-FGFR tyrosine kinase inhibitor erdafitinib in the phase 3 THOR trial.
5. Immune checkpoint inhibition improves outcome non-BRCA mutated ovarian cancer
   Patients with newly diagnosed advanced ovarian cancer without BRCA mutations who received durvalumab and olaparib in addition to the standard-of-care had improved progression-free survival compared with those who received the standard of care only, according to the interim results of DUO-O trial.
6. First-line nivolumab-AVD improves progression-free survival both in adult and paediatric patients with advanced stage Hodgkin lymphoma
   Results from the phase 3 SWOG S1826 trial showed that nivolumab-AVD improved progression-free survival compared to brentuximab vedotin-AVD, both in paediatric and adult patients. This is a key step towards harmonizing paediatric and adult therapy of Hodgkin lymphoma.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 26 June 202327 June 2024